Article
Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2018
Buder Anna, Hochmair Maximilian J, Schwab Sophia, Bundalo Tatjana, Schenk Peter, Errhalt Peter, Mikes Romana E, Absenger Gudrun, Patocka Kurt, Baumgartner Bernhard, Setinek Ulrike, Burghuber Otto C, Prosch Helmut, Pirker Robert, Filipits Martin
Abstract excerpt
INTRODUCTION: Osimertinib is standard treatment for patients with advanced EGFR T790M-mutated non-small-cell lung cancer who have been pre-treated with EGFR-tyrosine kinase inhibitors (TKIs). We studied whether cell-free plasma DNA for T790M detection can be used to select patients for osimertinib treatment in the clinical routine. METHODS: From April 2015 to November 2016, we included 119 patients with advanced...
Topics
- Acrylamides
- Adult
- Aged
- Aged, 80 and over
- Aniline Compounds
- Carcinoma, Non-Small-Cell Lung
- Female
- Humans
- Liquid Biopsy
- Lung Neoplasms
- Male
- Middle Aged
